Exicure (NASDAQ:XCUR – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.39) earnings per share (EPS) for the quarter, Zacks reports.
Exicure Trading Down 6.8%
Shares of XCUR traded down $0.29 during mid-day trading on Friday, reaching $3.96. The company’s stock had a trading volume of 28,624 shares, compared to its average volume of 64,493. Exicure has a 1-year low of $2.57 and a 1-year high of $36.00. The business has a 50-day simple moving average of $4.46 and a two-hundred day simple moving average of $7.05. The stock has a market cap of $25.03 million, a P/E ratio of -1.02 and a beta of 3.74.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Exicure in a report on Wednesday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Exicure has an average rating of “Sell”.
Exicure Company Profile
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Featured Articles
- Five stocks we like better than Exicure
- Why is the Ex-Dividend Date Significant to Investors?
- OpenAI’s Restructuring Sets up What Could Be the Biggest IPO Ever
- How to buy stock: A step-by-step guide for beginnersÂ
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
- How to Use High Beta Stocks to Maximize Your Investing Profits
- CrowdStrike Partners With CoreWeave But Investors Sell the News
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
